Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.
AEMD · Aethlon Medical Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Aethlon Medical agreed to merge with North Immunology, a two-step transaction expected to close in first calendar quarter 2027. The six-month net loss rose to $4,165,000, while cash was $6,486,639 as of September 30, 2026.
Aethlon Medical entered a merger agreement with North Immunology on September 17, 2026 and implemented workforce reductions. Cash was approximately $6.5 million as of September 30, 2026; quarterly operating expenses rose 77.2% to approximately $2.7 million.
Aethlon Medical, Inc. increased authorized common stock from 20,000,000 shares to 200,000,000 shares, following stockholder approval on October 1, 2026; the amendment became effective on October 7, 2026.
Aethlon Medical, Inc. stockholders did not approve a proposal to authorize 20,000,000 preferred shares because 204,122 votes in favor fell below the required 355,569; the Articles of Incorporation were not amended.
On October 1, 2026, Aethlon Medical stockholders elected five directors and approved increasing authorized common shares from 20,000,000 to 200,000,000, authorizing 20,000,000 preferred shares, and adding 100,000 shares to its 2020 Equity Incentive Plan.